Acute lung injury caused by cell death, high and potentially toxic concentrations of oxygen (hyperoxia), and the resulting excess fluid in the lungs (pulmonary edema), may be controlled by modulating ...
Hopes had not exactly soared high for Regeneron Pharmaceuticals Inc.'s combo pairing the angiopoietin2 (Ang2) antibody nesvacumab with approved Eylea (aflibercept), although "nobody would like it to ...
Aging causes a reduction of the protein Tie2, a risk factor for increased intraocular pressure and glaucoma. In this experiment, one eye of mice lacking Ang1 and Ang2 was injected with the premixed ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Visual acuity and anatomical improvements were achieved at all dose levels of nesvacumab combined with ...
With sales of vascular endothelial growth factor (VEGF) trap Eylea (aflibercept) as a monotherapy possibly slowing down, Regeneron Pharmaceuticals Inc. and Bayer AG have broadened their work in eye ...
Acute lung injury caused by cell death, high and potentially toxic concentrations of oxygen (hyperoxia), and the resulting excess fluid in the lungs (pulmonary edema), may be controlled by modulating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results